Given that PARP inhibitor resistance can be acquired in patients with recurring ovarian cancer, a randomized, two-arm phase II trial is currently being conducted in which these patients are being treated with AZD1775 alone or in combination with olaparib, with the aim of blocking the progression of tumor cells [192]. Here, PARP1 is linked to neoplasm.